Milestones in the pathogenesis and management of primary liver cancer

J Hepatol. 2020 Feb;72(2):209-214. doi: 10.1016/j.jhep.2019.11.006.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Bile Duct Neoplasms / drug therapy*
  • Bile Duct Neoplasms / pathology*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology*
  • Carcinoma, Hepatocellular / radiotherapy
  • Carcinoma, Hepatocellular / surgery
  • Chemoembolization, Therapeutic / methods
  • Chemoradiotherapy, Adjuvant / methods
  • Cholangiocarcinoma / drug therapy*
  • Cholangiocarcinoma / pathology*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / methods
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology*
  • Liver Neoplasms / radiotherapy
  • Liver Neoplasms / surgery
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antimetabolites, Antineoplastic
  • Immune Checkpoint Inhibitors
  • Protein Kinase Inhibitors